HC Wainwright Cuts Antares Pharma, Inc. (ATRS) Price Target to $3.50

An investor in NASDAQ:ATRS shares filed a lawsuit over alleged violations of Federal Securities Laws by Antares Pharma Inc. It now has negative earnings. The regular trading started at $1.94 but as the trading continued, the stock receded, settling the day with a fall of -5.29%. The stock decreased 0.52% or $0.98 on November 7, reaching $186.24.

Antares Pharma Cmn (NASDAQ:ATRS) as of recent trade, has shown weekly downbeat performance of -1.65% which was maintained at -52.27% in 1-month period. The stock exchanged hands with 1,628,771 numbers of shares compared to its average daily volume of 2.21M shares. Also, a 9.82% expansion in Antares Pharma, Inc. Antares Pharma has a 52 week low of $1.50 and a 52 week high of $4.09. Antares Pharma Cmn (NASDAQ:ATRS) has trailing twelve month Return on Assets of -25.7%, which is key indicator of how profitable a company is relative to its total assets. The firm earned "Buy" rating on Monday, August 7 by Jefferies. The rating was initiated by H.C. Wainwright on Friday, June 23 with "Buy". The stock closing price is now trading downward to its 50 day moving average with change of -36.48%, tumbled to its 20 day moving average with figure of -21.62% and behind its 200 day moving average with value -35.97%. The share price volatility of the stock remained at 7.09% for the month and by reducing the timeframe to just a week, the volatility stood at 7.67%. The mean rating score for this stock is at 2.50.

On October 20, 2017, Antares Pharma Inc announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for Xyosted, "indicat [ing] that the FDA can not approve the NDA in its present form". After $-0.02 actual earnings per share reported by Antares Pharma Inc for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

Several hedge funds have recently made changes to their positions in the company. 130,000 were reported by M&T Bancorporation. Benjamin F Edwards & Inc owns 6,000 shares. Prelude Mngmt Ltd accumulated 0.03% or 100,330 shares. Moreover, Gsa Capital Prtnrs Llp has 0.04% invested in Antares Pharma Inc (NASDAQ:ATRS). Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company's stock valued at $822,000 after acquiring an additional 26,847 shares during the last quarter. Prudential Fin holds 14,590 shares or 0% of its portfolio. California-based Fuller And Thaler Asset has invested 0.03% in Antares Pharma Inc (NASDAQ:ATRS). HC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of Antares Pharma in a research report on Sunday, September 10th. Bnp Paribas Arbitrage Sa has 15,090 shares. However, the institutional investors are observed to own 37.20% of the total shares. In current trading day Editas Medicine, Inc. California State Teachers Retirement Sys, California-based fund reported 254,600 shares. After a recent check, it is observed that the insiders for the firm now own 1.30% shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Like this


09 November 2017
Supernus Pharmaceuticals (SUPN) Earning Somewhat Favorable Press Coverage, Report Shows
It improved, as 22 investors sold SUPN shares while 82 reduced holdings. 55 funds opened positions while 82 raised stakes. Sizzling Stock Alert: Stericycle, Inc., (NASDAQ: SRCL), Supernus Pharmaceuticals, Inc ., ( NASDAQ: SUPN ), Inphi ...

09 November 2017
Endo International plc (NASDAQ:ENDP) Quarterly Sales Review
The company provided EPS guidance of $3.35-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.52. Oppenheimer Holdings, Inc. reissued a "hold" rating on shares of Endo International PLC in a report on Tuesday, August 8th.

09 November 2017
Kulicke & Soffa Industries Inc Sentiment Improves on Better Stock Potential
Signia Capital Management Llc holds 2.48% of its portfolio in Boston Private Financial Hldg Inc for 152,379 shares. Int Grp Inc reported 0% in Kulicke and Soffa Industries Inc. (NASDAQ:KLIC) on Thursday, August 6 to "Sell" rating.

09 November 2017
French nuclear reduction target now seen around 2030
The target was part of the previous Socialist government's 2015 energy transition law and was confirmed by new centrist president Emmanuel Macron's government.

09 November 2017
Couple accused of fabricating home invasion
Officers arrived to find the married couple had suffered gunshot wounds and were claiming that $7,000 was taken from a safe. The victims were transported to Central Florida Regional Hospital by ambulance with non-life-threatening injuries.

09 November 2017
What Does The Data Behind Itau Unibanco Holding SA (NYSE:ITUB) Suggest?
Finally, Renaissance Technologies LLC boosted its stake in Itau Unibanco Banco Holding SA by 565.0% in the first quarter. LLC now owns 12,157 shares of the bank's stock worth $134,000 after buying an additional 410 shares during the period.

09 November 2017
Do You Own Ultra Petroleum Corp. (NASDAQ:UPL) Shares?
The return on assets stands at 29.5%, Return on Equity now is -19.4% and the Return on Investment value is -3.9%. Taking a broader look brokerage firms' analysts on the street with an expectant view have Ultra Petroleum Corp.

09 November 2017
Alec Baldwin Claims Melania Trump 'Loves My Impersonation' of the President
Baldwin also went a step further, claiming the first lady told this person "that's exactly what he's like". Nothing to do with me, there's nothing amusing about it.

09 November 2017
Total to Buy Engie's Upstream LNG Portfolio for $1.49 Billion
Engie is to sell its upstream and midstream LNG business to compatriot Total, as it refocuses its energies on downstream gas. Engie will retain and expand its downstream LNG activities; regasification infrastructure and retail sales.

09 November 2017
Analyst Stock Ratings: Gartner, Inc. (IT), Thermo Fisher Scientific Inc. (TMO)
Analyst Thoughts About Barracuda Networks, Inc. (NYSEAMERICAN:BRN) has risen 19.25% since November 8, 2016 and is uptrending. Following the transaction, the director now owns 38,757 shares of the company's stock, valued at $6,790,226.40. (NYSE:TMO).